JP2008531710A5 - - Google Patents

Download PDF

Info

Publication number
JP2008531710A5
JP2008531710A5 JP2007558177A JP2007558177A JP2008531710A5 JP 2008531710 A5 JP2008531710 A5 JP 2008531710A5 JP 2007558177 A JP2007558177 A JP 2007558177A JP 2007558177 A JP2007558177 A JP 2007558177A JP 2008531710 A5 JP2008531710 A5 JP 2008531710A5
Authority
JP
Japan
Prior art keywords
agent
cell
sod protein
pyrimethamine
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007558177A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008531710A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/007257 external-priority patent/WO2006096405A2/en
Publication of JP2008531710A publication Critical patent/JP2008531710A/ja
Publication of JP2008531710A5 publication Critical patent/JP2008531710A5/ja
Pending legal-status Critical Current

Links

JP2007558177A 2005-03-04 2006-03-01 神経変性疾患の調節 Pending JP2008531710A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65850505P 2005-03-04 2005-03-04
PCT/US2006/007257 WO2006096405A2 (en) 2005-03-04 2006-03-01 Treatment of amyotrophic lateral sclerosis with pyrimethamine and analogues

Publications (2)

Publication Number Publication Date
JP2008531710A JP2008531710A (ja) 2008-08-14
JP2008531710A5 true JP2008531710A5 (enExample) 2009-11-26

Family

ID=36953835

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007558177A Pending JP2008531710A (ja) 2005-03-04 2006-03-01 神経変性疾患の調節

Country Status (10)

Country Link
US (1) US20060211645A1 (enExample)
EP (1) EP1917017B1 (enExample)
JP (1) JP2008531710A (enExample)
CN (1) CN101184493A (enExample)
AT (1) ATE456953T1 (enExample)
AU (1) AU2006220919A1 (enExample)
CA (1) CA2600067A1 (enExample)
DE (1) DE602006012115D1 (enExample)
ES (1) ES2340708T3 (enExample)
WO (1) WO2006096405A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006096404A2 (en) * 2005-03-04 2006-09-14 Alsgen, Inc Treatment of amyotrophic lateral sclerosis with norethindrone and anal0gues
US20060211673A1 (en) * 2005-03-04 2006-09-21 Alsgen, Llc Modulation of neurodegenerative diseases through the estrogen receptor
US20070135437A1 (en) * 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
US20080153094A1 (en) * 2006-10-13 2008-06-26 Minor James M Reduction of nonspecific binding in nucleic acid assays and nucleic acid synthesis reactions
US20110092554A1 (en) * 2007-11-19 2011-04-21 Richard Chesworth 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders
AU2008345573B2 (en) 2007-12-20 2013-12-19 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
US9040538B2 (en) * 2009-05-21 2015-05-26 Universite Laval Pyrimidines as novel therapeutic agents
GB201015079D0 (en) * 2010-09-10 2010-10-27 Helperby Therapeutics Ltd Novel use
KR20180084153A (ko) 2011-06-10 2018-07-24 메르크 파텐트 게엠베하 Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법
CN104398517A (zh) * 2014-11-28 2015-03-11 四川大学 乙胺嘧啶的新用途及治疗肿瘤的药物组合物
WO2021096199A1 (ko) * 2019-11-11 2021-05-20 에스케이케미칼 주식회사 피리메타민을 유효성분으로 포함하는 면역 관련 질환의 치료 또는 예방용 약학 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231170A (en) * 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
US5866562A (en) * 1996-10-25 1999-02-02 Bayer Aktiengesellschaft Ring-bridged bis-quinolines
US7442629B2 (en) * 2004-09-24 2008-10-28 President & Fellows Of Harvard College Femtosecond laser-induced formation of submicrometer spikes on a semiconductor substrate
ES2330090T3 (es) * 2001-11-28 2009-12-04 Btg International Limited Agentes profilacticos o remedios para la enfermedad de alzheimer o unhibidores de la fibrosis de las proteinas amiloides que contiene compuestos de heteroarilo que contiene nitrogeno.
KR20040099324A (ko) * 2002-03-13 2004-11-26 유로-셀티큐 에스.에이. 아릴 치환된 피리미딘 및 이것의 용도
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
WO2006096404A2 (en) * 2005-03-04 2006-09-14 Alsgen, Inc Treatment of amyotrophic lateral sclerosis with norethindrone and anal0gues
US20070135437A1 (en) * 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases

Similar Documents

Publication Publication Date Title
NO2020004I1 (no) Larotrektinib og/eller farmasøytisk akseptable salter derav, særlig larotrektinibsulfat inkludert larotrektinibhydrogensulfat
JP2010539123A5 (enExample)
JP2011511805A5 (enExample)
JP2007527914A5 (enExample)
JP2010535151A5 (enExample)
IL193702A (en) Pharmaceutical preparation containing human embryonic stem cells, methods of manufacture and use thereof
IL192374A0 (en) Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol
BRPI0719762A2 (pt) Anticorpo, composição farmacêutica, polipeptídeo, polinucleotídeo isolado, plasmídeo, célula isolada, e, métodos para fabricar um polipeptídeo que se liga especificamente ao receptor il-17 a, para tratar um estado de doença associado com a ativação de il-17ra em um paciente, para inibir a produção de pelo menos uma citocina, quimiocina, metaloproteinase de matriz ou contra molécula associada com a ativação de il-17ra e para tratar inflamação e doneça autoimune em um paciente.
JP2008531710A5 (enExample)
NO343776B1 (no) Forbindelse som modulerer farmakokinetikkegenskaper til terapeutika, dens anvendelse i terapi og farmasøytisk sammensetning derav.
IL189555A0 (en) Compositions of cells enriched for combinations of various stem and progenitor cell populations, methods of use thereof and methods of private banking thereof
JP2007517055A5 (enExample)
NO20085420L (no) Farmasøytisk formulering med fenylefrin og preparater for absorpsjon i tykktarmen
JP2008013542A5 (enExample)
EP2213746A4 (en) CELL FOR THE PREPARATION OF EXOGENEO PROTEIN AND MANUFACTURING PROCEDURE ON THE CELL
IL198845A (en) An extended-release peptide preparation, a process for its preparation and use for drug preparation
TWD137077S1 (zh) 燃料電池之計量閥
JP2010528620A5 (enExample)
IL179884A0 (en) Fuel cells, micro-fuel cells and methods for the production thereof
ATE531715T1 (de) 1,3-dihydro-2h-pyrroloä3.2-büpyridin-2-onderiva e,deren herstellung und deren therapeutische verwendungen
JP2008536808A5 (enExample)
JP2011505864A5 (enExample)
EP2380973A4 (en) PREPARATION BASED ON REPROGRAMMABLE CELL SIGNALING STEM CELLS, METHOD OF MAKING THE PREPARATION AND USE THEREOF
ZA200805793B (en) Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol
JP2009536193A5 (enExample)